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Aim: To give the surgeon an overview of Primary Sjögren’s Syndrome, its pathophysiology, 
diagnosis and management thus giving insight into why labial gland biopsies are required. 
The authors also aim to make the operating surgeon aware of their role, responsibility and 
medicolegal factors to be considered prior to undertaking a labial gland biopsy. 
Materials and Methods: A literature search of PubMed (MEDLINE), Cochrane and 
EMBASE electronic databases using the search terms “Primary Sjӧgren’s Syndrome”, 
“Diagnostic Criteria for Sjӧgren’s Syndrome”, “Labial Gland Biopsy”, “Labial Gland Biopsy 
Complications”, “Diagnostic Imaging for Sjӧgren’s Syndrome”, and “Medicolegal 
Responsibility of Surgeons”. Title and then abstract were reviewed to determine relevance. 
Widely used guidelines were identified, indications for biopsy and the risks posed by surgery 
considered. Medicolegal advice was formally sought via a medical/dental defence union.  
Results: The authors considered the available evidence and medicolegal advice and applied 
this knowledge to the clinical setting. A preoperative checklist for consideration prior to 
labial gland biopsy was developed.  
Conclusions: Labial gland biopsy is an invasive procedure with potential to cause 
postoperative complications. The operator assumes ultimate responsibility for the procedure. 
Every surgeon aims to ensure safe surgical practice, in the best interest of the patient. Here 








Rationale for Study: This paper came about due to the difficulties a colleague faced after 
performing a labial gland biopsy on a patient who subsequently experienced paraesthesia.  
Principle Findings: Labial gland biopsy is a procedure with potential to cause complications. 
Current medicolegal advice is that the surgeon assumes ultimate responsibility for the 
procedure itself and must be cognisant with the underpinning rationale and current evidence 
relevant to the potential diagnostic value of this invasive procedure.  
Practical Implications: We have developed a tool to use prior to performing a labial gland 
biopsy to facilitate the necessary checks. 
 
Introduction 
Sjӧgren’s Syndrome (SS) is a chronic inflammatory multisystem, progressive, autoimmune 
exocrinopathy. It mainly manifests in abnormal ocular and salivary gland function; however 
other organs can be affected in more than 30% of patients1. The pathogenesis of SS is not 
fully understood. Nevertheless, it is known to be an autoimmune disease with anti-nuclear 
antibodies produced targeting Ro and La found in many cases2. SS associated with an 
underlying condition is classified as secondary SS and when presenting in the absence of 
other related pathology as primary Sjӧgren’s Syndrome (pSS)3. Here we focus on the role of 
the labial gland biopsy (LgBx) in the diagnosis and future management of pSS. 
 
pSS is still a complex and often misunderstood disease with significant quality of life 
implications for the patients. It can manifest in different ways, affecting salivary and lacrimal 
flow but also causing major salivary gland swelling and associated pain, cutaneous and 
genital dryness, fatigue, arthralgia and myalgia4. Thus, the prompt diagnosis and management 
of the disease is imperative but can be hindered by the spectrum of signs and symptoms 








Diagnosis of pSS 
Diagnosis of Sjӧgren’s involves a multidisciplinary approach often involving 
rheumatologists, ophthalmologists, oral surgeons and oral physicians. 
Diagnostic Criteria 
Over the last two decades, three main sets of validated criteria have been published. In 2002 
the America-European Consensus Group (AECG) diagnostic criteria for pSS5 were published 




In 2012 the American College for Rheumatology (ACR) proposed new diagnostic criteria 
which were aimed at selection of patients prior to enrolment into clinical trials6. However, 
these criteria have not yet been validated by epidemiological studies. Whilst there are 
differences between the AECG and ACR criteria, concordance is high7. More recently the 
2016 ACR/European League Against Rheumatism (EULAR) criteria were published 
consequent to collaboration between the AECG and ACR/ Sjӧgren’s International 
Collaborative Clinical Alliance (SICCA)8. Oral surgeons should be aware that a labial gland 
biopsy is a component of diagnosis in all three systems and that individual rheumatologists 
may refer to any of the above-mentioned criteria in establishing a diagnosis of pSS. Hence it 
is important that the surgeon is aware of the relevant criteria utilised to consider the potential 
diagnostic yield of a labial gland biopsy in individual patients. If there is any confusion, 
clarification of the specific criteria should be sought. Considering the multiple criteria in 
clinical use, for purposes of this paper we will henceforth refer solely to the most recent 2016 
ACR/EULAR criteria8 (Table 2). 
The 2016 ACR/EULAR criteria8 require that patients initially must meet inclusion criteria set 
out in Table 2 below. They must thereafter have positive results to a threshold of the 




To be able to give a diagnosis the patient must score 4 or more when the weights of each 
individual criteria are considered to fulfil the 2016 ACR/EULAR classification8 (Table 2). 
Thus, if a patient had a positive anti SSA/Ro extractable nuclear antigens (ENA) (heavily 
weighted by the criteria and given a score of 3) and positive Schirmer’s Test (reduced 
lacrimal flow) they would fulfil the criteria for having pSS, not requiring further tests to 
prove it. The labial gland biopsy is another heavily weighted criterion to that also scores 3 in 
this classification and can therefore be utilised by clinicians to establish a diagnosis of SS.  
To add further complexity to the diagnostic process, advances in ultrasonography have 
resulted in this imaging modality being considered to replace radiation modality dependent 
imaging modalities such as sialography or scintography9. Within Oral Medicine Specialist 
practice in the UK ultrasonography is becoming the prime imaging modality utilized, in 
preference to radiation dependent modalities. In the future an ultrasound may be deemed to 
satisfy the AECG imaging criterion without need of recourse to radiation dependent 
investigations. Whilst there are no current criteria set for the utilisation of an imaging 
modality in the current ACR/EULAR 2016 guidelines, provision for future adoption has been 
referred to by the group8. 
 
Chairside investigations: 
There are common chairside and laboratory investigations for pSS, these are testing lacrimal 
function, salivary flow and ANA and ENA analysis. A Schirmer’s test is a simple chairside 
test that can measure lacrimal function. A graduated strip of filter paper with specially shaped 
ends is inserted into the conjunctival fornix of the eye and after 5 minutes the length of fluid 
tracking along the paper is recorded (<5mm tear wetting track indicates abnormal lacrimal 
activity)10. Unstimulated whole saliva flow rate measurement described by Navazesh and 
Kumar11 is measured by passively collecting the patient’s saliva in a calibrated tube over a 
15-minute period (<1.5mL indicates an abnormal result). This test has an important role in 
differentiating between patient reported dry mouth and clinically demonstrated 
hyposalivation. The presence of anti SSA/Ro antibodies is assessed via sending an 
appropriate blood sample to the immunology laboratory.  
Investigations through referral: 
Suspected cases of pSS are often referred from primary care to ophthalmology and/or 
rheumatology departments. Ocular staining scores are usually accessed via a referral to 
ophthalmology. Corneal integrity is assessed using Fluorescein and conjunctival health is 
visualised using Rose Bengal or lissamine green12. Rheumatology departments routinely 
manage Sjӧgren’s disease. Their input is required when treatment provided in primary care is 
not managing patient symptoms and systemic complications are suspected. They will carry 
out basic chairside investigations listed above and may enlist input from ophthalmologists 
and potentially oral surgeons or oral physicians for the provision of a biopsy of labial gland 
tissue. 
Labial Gland Biopsy 
Procedure 
Due to accessibility, avoidance of skin incision, ease of anaesthesia, lack of complicating 
structures and the presence of many minor salivary glands; the lower lip is the anatomical 
position of choice for salivary gland biopsy13,14. The procedure is normally carried out under 
local anaesthesia. A 1-1.5cm superficial incision is made lateral to the midline (as this area 
holds the most glands), blunt dissection is used to arrive deep to the mucous membrane and 
superficial to the orbicularis oris muscle. Vertical or horizontal incision can be made and 
there is no conclusive evidence to suggest one technique is better than the other. However, 
vertical incision is less likely to transect the mental nerve, though this should be unlikely due 
to the superficial nature of the initial incision. A sample of 6-8 glands is sent in formalin 
solution for histopathological analysis. The sample will be mounted in wax then stained with 
haematoxylin and eosin (H&E) to assess focal lymphocytic sialadenitis (FLS). The request to 
the pathologist should include asking for the focus score, the presence or absence of germinal 
centre-like structures and IgG4 staining15. 
 
A focus is defined as an aggregate of 50 or more lymphocytes per 4 mm2 glandular tissue 
adjacent to normal mucous acini16. Daniels et al (as part of the Sjӧgren’s International 
Collaborative Clinical Alliance (SICCA)) studied the histopathological results of a large 
cohort of 1726 patients with signs or symptoms linked to primary or secondary Sjӧgren’s 
syndrome. They found that a diagnosis of focal lymphocytic sialadenitis with a focal score 
(FS) of greater than or equal to 1 per 4mm2 versus a FS of less than 1 with non-specific or 
sclerosing chronic sialadenitis was strongly associated with the ocular and serological 
components of Sjӧgren’s syndrome and reflects Sjӧgren’s syndrome autoimmunity17. 
Depending on the pSS diagnostic criteria  being used, a focus score cutoff of either “1” or 
“greater than 1” is considered positive for Sjӧgren’s syndrome18 (Table 3). 
Table 3 
Complications 
As with any minor oral surgery procedure there are risks involved. Post-operative concerns 
include bleeding, bruising, swelling and pain. Reported complications range from these 
routine transient issues to damage to adjacent minor salivary glands and permanent 
paraesthesia of the mental nerve.  Anatomical dissection of the lower lip has shown patterns 
of neurological fibres in the lower lip indicating that there is no completely safe anatomical 
space for minor oral procedures to the inner mucosal aspect of the lower lip19. 
 
Colella et al performed a systematic review of the literature between January 1990 and 
January 2010 that included 21 studies of minor salivary gland biopsy. Within these studies 
patients reported disorders of lip sensitivity for up to 6 months occurring as frequently as 
11%13. Patients reported neurological complications lasting between 7-14 days and one 
patient over 2 years. While short term neurological complications may occur, the long term 
risk will be of importance to patients. Pijpe reported in a 2006 study a permanent sensory loss 
of 6%20. In 2014 Centelles et al performed a meta-analysis of cases looking at the incidence 
of neurological complication in relation to the type of incision and found an initial incidence 
of 11.7%, this can persist in up to 6% of patients beyond 6 months21,22. In these persistent 
cases the paraesthesia was reported to be permanent. Thorough knowledge of the possible 
postoperative complications is required to gain fully informed consent. It would be 
reasonable to discuss the above studies with patients and give them an estimate of 12% 
chance of developing altered sensation of the mental nerve that may persist beyond 6 months 




Sensitivity and Specificity 
In addition to the risk of complications there is also the risk of a LgBx providing in an 
inconclusive outcome. Focus scores of 2 to 6 have been detected in biopsies from 15% of 
healthy volunteers with no sicca symptoms in one study of 54 participants23. False negative 
results were found in 20 to 40% of biopsies taken in another study24 and in a further study 
revisiting the analysis of biopsy samples resulted in the change of diagnoses in 32 out of 60 
patients’ cases25. This difficulty and variability of interpretation of lip gland biopsies between 
pathologists is recognised as part of recent consensus reports and cohort studies26,27,28. The 
need for standardisation of interpretation of histopathological results between 
histopathologists has been acknowledged by rheumatologists29. However, as demonstrated in 
the aforementioned studies general pathologists have a much higher variation in reporting of 
biopsy results than the specialist head and neck pathologists that checked the results. The 
potential inconsistency of sensitivity and specificity should be relayed to the patient when 
discussing the benefits and drawbacks of the procedure as another part of an informed 
consent process, but reassurance given if it is known that a specialist pathologist will be 
available. Patients consenting to this surgical procedure also need to be aware of the 
difficulties in biopsy interpretation that may preclude a definitive diagnostic outcome. 
 
Management of pSS 
Management of pSS is dependent on the individual disease characteristics experienced by 
each patient. Dryness of the mouth and eyes (known collectively as Sicca Syndrome) are the 
most common complaints by patients diagnosed with pSS, occurring individually in 98% and 
in combination in 89% of patients in a large (6110 patient) case series11. Chronic eye 
irritation, difficulty eating and speaking and dental disease all ensue from lack of lacrimal 
and salivary fluids15. If detected early these can be treated with topical lubrication, but 
disease progression can result in permanent visual disturbance and potentially tooth loss due 
to caries and periodontal disease. The awareness of and monitoring by ophthalmologists and 
dental practitioners is essential. 
Exocrine glandular swelling due to focal, mononuclear cell infiltrate accumulating around 
ducts, encompassing and replacing secretory cells results in acute and chronic inflammation 
occurring recurrently in pSS30. Glandular enlargement, especially if recent onset and 
unilateral should be investigated for underlying pathology. In a UK-based study of 152 
patients with pSS 28.3% developed malignancy over a 25-year follow-up period, 1.72 cases 
per year equating to an incidence rate of 1.1%. The majority of those patients developing 
non-Hodgkin lymphoma30. There is ongoing research into the predictive value of LgBx on 
the progression of pSS to lymphoma. A recent review by Kroese et al suggests that more 
research and further consensus on the interpretation of the labial gland biopsy is required 
before this can be considered a reproducible and reliable test31. Other severe systemic 
manifestations can arise affecting the skin, lungs, kidneys and peripheral and central nervous 
systems15. Treatments for pSS can range from topical eye drops and salivary substitutes for 
sicca symptoms to systemic steroids and disease modifying anti-rheumatic drugs 
(DMARDs)32. However, some pSS patients have limited symptoms and require no medical 
intervention. Considering the spectrum of disease and its management, pSS diagnosis will 
have different levels of significance on a case by case basis. 
  
Medicolegal Implications and Consent 
Medicolegal input was formally sought via a medical/dental defence union regarding the legal-
standing of the surgeon performing a LgBx. The Senior Dento-legal Advisor concluded that if 
a patient is referred to a practitioner for an investigative procedure or for treatment, the 
practitioner accepting the referral has a professional and legal obligation to make every 
reasonable effort to determine whether that procedure or treatment is appropriate and necessary 
for the individual patient, hence in the patient’s best interest. To simply carry out the requested 
treatment without question would render the practitioner open to justifiable criticism as 
indicated by the below citation from the GDC’s document Standards for the Dental Team33 




A labial gland biopsy can be requested by referral from a non-dental specialty. Clearly, an oral 
surgeon cannot be expected to possess the same specialist knowledge of disease management 
regarding this specific subject matter compared with a referring consultant rheumatologist or 
an oral medicine specialist. Nevertheless, the oral surgeon accepting a referral must have 
sufficient knowledge of the indications for the procedure or treatment requested by the 
referring practitioner such that they can assess whether it is appropriate, in the correct sequence 
of the investigation pathway, necessary for the individual patient, and thus in the patient’s best 
interest. 
Consent is not a one-off event but an ongoing process and will start with the referring 
practitioner explaining to the patient about their condition, the options for investigation and 
treatment, and their pros, cons and risks, and the reason for the referral. That dialogue will 
continue when the patient attends the oral surgeon accepting the referral.  Whilst responsibility 
for obtaining consent is a shared responsibility between the referrer and the operating surgeon, 
it rests predominantly with the practitioner accepting the referral. The inference is that the oral 
surgeon must therefore have sufficient knowledge of the indications and underpinning rationale 
including the ability to balance the diagnostic gain against the potential harms whilst respecting 
the patient’s views. This is critical in terms of obtaining informed consent in line with the 
Montgomery judgement34. 
If the practitioner accepting the referral is of the opinion the treatment requested by the 
referring practitioner is inappropriate, unnecessary, and not in the patient’s best interest, then 
in line with paragraph 6.4.2 of the GDC’s Standards for the Dental Team33, they should contact 
the referring practitioner and seek to resolve the concern. If they cannot satisfactorily resolve 
their concern, they should decline to carry out the procedure or treatment as per paragraph 6.4.2 
of the GDC’s Standards for the Dental Team33, explaining to both patient and referring 
practitioner their reasons for so declining. It is a fundamental clinical principle that a dental or 
medical professional should not be compelled to carry out an investigative procedure or a 
treatment with which they disagree because they do not consider it is appropriate, necessary, 
in the patient’s best interest, and in line with current accepted practice and teaching as would 
be supported by a responsible body of clinical opinion33. 
Shared Care Decision Making 
Expert input from a medical/dental defence union and the General Dental Council (discussed 
previously) dictate that a surgeon on accepting a referral needs to be appropriately satisfied 
that the investigation is required, and that consent derived from the patient does not restrict 
itself to that of potential complications but also to indications for such a procedure. They must 
also be able to evaluate what the potential impact (or otherwise) to the condition the diagnostic 
yield of the LgBx would have. The expectation is that oral surgeons who, as part of their clinical 
responsibilities are performing labial gland biopsies, need to be familiar with the most widely 
utilised AECG criteria and generally with the current literature around pSS as a multi-system 
disease, as well as current developments in the management of this condition. 
The authors have developed a checklist to guide oral surgeons in their assessment of patients. 
However, each patient must be treated as an individual and assessed on a case-by case basis. 
A thorough knowledge of the current literature and the background of patients being referred 
in for surgical investigations is required for labial gland biopsies and other interventions with 
associated morbidity. Though these patients may have been referred by specialists, the 
operating surgeon must appreciate the indications for and the risks and benefits of any 
procedure undertaken. 
 
Using the literature, expert opinion and recent developments we have established our own 




• Has the referrer outlined the clinical justification for this investigation?  
• Has the referrer outlined how the potential diagnostic yield from this investigation 
will change the patient’s management? 
• Has the referrer exhausted all non-invasive investigations that can be utilised? 
• Has the patient understood the reason for this investigation? 
• Has the patient understood the implications of a positive or negative diagnosis within 
the context of their future management? 





The authors suggest that the referring practitioner has informed the clinician requested to take 
a LgBx of the diagnostic criteria that they are using prior to referral. If a clinician wishes to 
implement a checklist like the one above, they may wish to inform the referring team and 
possibly involve them in adaptation of the list to any specific local departmental needs. 
 
Discussion 
LgBx remains a key investigative modality in both the AECG and the 2016 ACR/ EULAR 
criteria for diagnosis of pSS. Consequently, oral surgeons in receipt of referrals from other 
medical specialties (such as rheumatology) asking for labial gland biopsies to be carried out 
will find that negotiating the differing stipulated requirements of each of these criteria might 
be challenging. If not included in the referral, and if there is any ambiguity, it would be 
advisable to enquire as to the criteria used by the referrer. 
It is possible that a positive LgBx will not result in confirmation of a diagnosis of pSS if the 
AECG criteria are referred to but will do so with the 2016 ACR/ EULAR criteria. It is 
reasonable, in our opinion, for an oral surgeon to consider a LgBx referral with due critical 
consideration as it is an invasive investigation with potential significant complications. The 
diagnostic yield will need to be considered as part of the decision-making process to be 
discussed with patient. This will vary for example in a case where systemic treatment with 
potentially harmful side-effects are being considered should the diagnosis of pSS be 
confirmed. In the latter case the significance of a formal confirmation of pSS may outweigh 
the potential surgical risks. Another scenario where a diagnosis will not result in a change to 
the patient’s management and hence have no functional benefit to the patient may result in a 
consideration that the surgical risks are not in the patient’s best interest. pSS is a long-term 
condition that will require long-term follow up and management. Its signs and symptoms can 
fluctuate over time. A specific diagnosis may be of benefit in the long term as treatment 
options change and in giving the patient reassurance to the underlying cause of their ailments. 
The patient’s views are key to this shared care decision making approach. Hence it is 
reasonable to assume that an oral surgeon follows the following principles (as outlined in the 
checklist): 
 
• Has the referrer outlined the clinical justification for this investigation?  
• Has the referrer outlined how the potential diagnostic yield from this 
investigation will change the patient’s management? 
Will the result influence the patient’s management? Across the disease spectrum of pSS 
management strategies may range from simply managing xerophthalmia and xerostomia 
related symptoms to consideration of disease-modifying anti-rheumatic drugs (DMARDs) to 
manage systemic symptoms. It is reasonable to consider that a rheumatologist planning the 
introduction of a DMARD may wish to exhaust all potential avenues to obtain evidence to 
substantiate a diagnosis. As indicated above there are groups of patients who may have the 
range of signs and symptoms of pSS but lack investigation-based evidence to substantiate a 
diagnosis according to the AECG or ACR criteria. In such cases the Rheumatologist is placed 
in challenging position to treat the condition without the benefit of a formal diagnosis and 
hence may request a LgBx reasonably in our opinion even in situations where a positive 
LgBx investigation will not result in a formal diagnosis of pSS according to the AECG or 
ACR criteria. Within this context the validity of such indications will be based upon the 
diagnostic yield that may be derived from this investigation and how this diagnostic yield 
may potentially influence patient management. 
• Has the referrer exhausted all non-invasive investigations that can be utilised? 
Have the relatively non-invasive investigations such as blood-based investigation and 
imaging have been performed before proceeding to LgBx? Depending on the facilities 
available at particular institutions there may also be an opportunity to utilize non-invasive 
investigations such as ultrasound imaging. 
• Has the patient understood the reason for this investigation? 
• Has the patient understood the implications of a positive or negative diagnosis 
within the context of their future management? 
Patients’ views are critical within the required shared care decision making approach 
underpinning a decision to proceed with LgBx. For example, some patients may indicate that 
a quest for a formal diagnosis is important to them whilst for others establishing a formal 
diagnosis is only considered as critical if the actual management of the condition may 
potentially change with confirmation of a formal diagnosis. 
• Has the patient been informed of the short term and long-term complications of 
the surgical procedure? 
Post-operative surgical considerations to discuss include; pain, swelling, bleeding, bruising, 
infection and temporary or permanent numbness to the lower lip and chin. The patient should 
be informed that paraesthesia has been reported in one study with an incidence of up to 
11.7% at 6 months post LgBx, and that there is around a 6% chance that the altered sensation 
could be permanent, as reported in another, separate study.  
 
 
We have provided examples of clinical scenarios to illustrate the complexity around the 




The decision to proceed to performing a LgBx to aid in the diagnosis of pSS is not a 
straightforward one. Due to the anatomical position of the labial glands, biopsy in this region 
has the potential to cause postoperative complications. The analysis of the resulting tissue can 
occasionally be unreliable and there are ongoing studies that evaluate and aim to solve this 
issue26,29.  
The oral surgeon in receipt of a referral to perform a LgBx must be familiar with the rationale 
and current evidence relevant to the potential diagnostic value of this procedure and have in 
depth knowledge of potential complications, enough to discuss this in detail with the patient 
and inform the consent process. The decision to perform the biopsy must be considered on an 
individual patient basis and with input from multiple specialties in a shared care decision 
making process.  
Follow-up work could include evaluation of the use of the checklist on clinic prior to listing a 












1. Franceschini F, Cavazzana I, Andreoli L, Tincani A. The 2016 classification criteria 
for primary Sjogren's syndrome: what's new? BMC Med. 2017;15(1):69. 
2. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity. 
2005;38(1):55-63. 
3. Patel R, Shahane A. The epidemiology of Sjögren's syndrome. Clin Epidemiol. 
2014;6:247-55. 
4. Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. 
Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. 
5. Brito-Zerón P, Theander E, Baldini C, Seror R, Retamozo S, Quartuccio L, et al. 
Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical 
recommendations. Expert Rev Clin Immunol. 2016;12(2):137-56. 
6. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. 
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-
driven, expert consensus approach in the Sjögren's International Collaborative Clinical 
Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475-87. 
7. Rasmussen A, Ice JA, Li H, Grundahl K, Kelly JA, Radfar L, et al. Comparison of the 
American-European Consensus Group Sjogren's syndrome classification criteria to newly 
proposed American College of Rheumatology criteria in a large, carefully characterised sicca 
cohort. Ann Rheum Dis. 2014;73(1):31-8. 
8. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 
2016 American College of Rheumatology/European League Against Rheumatism 
classification criteria for primary Sjögren's syndrome: A consensus and data-driven 
methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9-16. 
9. Astorri E, Sutcliffe N, Richards PS, Suchak K, Pitzalis C, Bombardieri M, et al. 
Ultrasound of the salivary glands is a strong predictor of labial gland biopsy histopathology 
in patients with sicca symptoms. J Oral Pathol Med. 2016;45(6):450-454. 
10. Schirmer O. Studien zur Physiologie and Pathologie der Tranenabsonderung und 
Tranenabfuhr. Alb Graf Archiv Othal. 1903;56(2)197 
11. Navazesh M, Kumar SK, Dentistry UoSCSo. Measuring salivary flow: challenges and 
opportunities. J Am Dent Assoc. 2008;139 Suppl:35S-40S. 
12.  Kim J. The use of vital dyes in corneal disease. Curr Op in Opth. 2000, 11:241-247 
13. Colella G, Cannavale R, Vicidomini A, Itro A. Salivary gland biopsy: a 
comprehensive review of techniques and related complications. Rheumatology (Oxford). 
2010;49(11):2117-2121. 
14. Saruhanoğlu A, Atikler M, Ergun S, Ofluoğlu D, Tanyeri H. Comparison of two 
different labial salivary gland biopsy incision techniques: a randomized clinical trial. Med 
Oral Patol Oral Cir Bucal. 2013;18(6):e851-5. 
15. Rischmueller M, Tieu J, Lester S. Primary Sjögren's syndrome. Best Pract Res Clin 
Rheumatol. 2016;30(1):189-220. 
16. van Stein-Callenfels D, Tan J, Bloemena E, van Vugt RM, Voskuyl AE, Santana NT, 
et al. The role of a labial salivary gland biopsy in the diagnostic procedure for Sjögren's 
syndrome; a study of 94 cases. Med Oral Patol Oral Cir Bucal. 2014;19(4):e372-6. 
17. Daniels TE, Cox D, Shiboski CH, Schiodt M, Wu A, Lanfranchi H, et al. 
Associations between salivary gland histopathologic diagnoses and phenotypic features of 
Sjogren’s Syndrome among 1,726 registry participants. Arth Rheum. 2011;63(7):2021-2030 
18. Delli K, Vissink A, Spijkervet FK. Salivary gland biopsy for Sjögren's syndrome. 
Oral Maxillofac Surg Clin North Am. 2014;26(1):23-33. 
19.  Alsaad K, Lee TC, McCartan B. An anatomical study of the cutaneous branches of 
the mental nerve. Int J Oral Maxillofac Surg. 2003;32(3):325-33 
20.  Pijpe J, Kalk WWI, van der Wal JE, Vissink A, Kluin PhM, Roodenburg H et al. 
Parotid gland biopsy compared with labial biopsy in the diagnosis of Sjogren’s syndrome. 
Rheum. 2007;46(2):335-341 
21. Centelles P, Sanchez-Sanchez M, Costa-Bouzas J, Seone-Romero JM, Seoane J, 
Takkouche B. Neurological adverse events related to lip biopsy in patients suspicious for 
Sjorgren's Syndrome: a systematic review and prevalence meta-analysis. Rhematol. 
2014;53:1208-1214 
22. Caporali R, Bonacci E, Epis O, Bobbio-Pallavicini F, Morbini P, Montecucco C. 
Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 
procedures performed at a single center. Arthritis Rheum. 2008;59(5):714-20. 
23. Radfar L, Kleiner DE, Fox PC, Pillemer SR. Prevalence and clinical significance of 
lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum. 2002 Oct 
15;47(5):520-4 
24.  Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and 
treatment. A review. Arch Med Res. 2002 Mar-Apr;33(2):95-106 
25. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of 
labial minor salivary gland biopsies. J Rheumatol. 2002 May;29(5):938-44 
26.  Fisher BA, Jonsson R, Daniels T, Bombardieri, Brown RM, Morgan P, et al. 
Standardisation of labial salivary gland histopathology in clinical trials in primary Sjogren’s 
syndrome. Ann Rheum Dis. 2017;76(7):1161-1168 
27.  Fisher BA, Brown RM, Bowman SJ, et al. A review of salivary gland histopathology 
in primary Sjogren’s Syndrome with a focus on its potential as a clinical trials biomarker. 
Ann Rheum Dis. 2015;74:1645-50 
28. Costa S, Quintin-Roue I, Lesourd A, Jousse-Joulin S, Berthelot JM, Hachulla E, et al. 
Reliability of histopathological salivary gland biopsy assessment in Sjogren’s syndrome: a 
multicentre cohort study. Rheum. 2015;54(6):1056-64 
29. Fox RI. Standardisation of labial salivary gland biopsies in Sjogren's syndrome: 
importance for the practicing rheumatologist. Ann Rheum Dis. 2017;76:1159-1160 
30. Abrol E, González-Pulido C, Praena-Fernández JM, Isenberg DA. A retrospective 
study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year 
experience. Clin Med (Lond). 2014;14(2):157-64. 
31. Kroes F, Haacke E, Bombardieri M. Clin Exp Rheum. 2018;36(Suppl.112):S222-233 
32. Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The 
Diagnosis and Treatment of Sjögren's Syndrome. Dtsch Arztebl Int. 2017;114(20):354-61. 
33. Affleck P, Holt J, Baker R. Must or should? Interpreting 'Standards for the dental 
team'. Br Dent J. 2017;223(2):77-8. 
34. Smith A. Montgomery and implications for clinical practice. Brit J Obs Gyn. 
2017;124(8):114-1151. 
 
